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The El open reading frame of bovine papillomavirus (BPV) was expressed as a RecA-El fusion protein in
Escherichia coli. The bacterially expressed RecA-El protein exhibited sequence-specific DNA binding activity;
strong binding to the region from nucleotides 7819 to 93 on the BPV genome (designated region A) and weak
binding to the adjacent region from nucleotides 7457 to 7818 (region B) were observed. The interaction between
the BPV-derived RecA-El protein and region A appeared to be highly specific for BPV DNA, as no comparable
binding was detected with heterologous papillomavirus DNAs. Binding to region A was eliminated by digestion
of region A at the unique HpaI site, which suggests that the RecA-El binding site(s) was at or near the HpaI
recognition sequence. Binding to region B but not region A was observed when nuclear extracts from ID13 cells
were used as a source of El proteins. The absence of region A binding by ID13 extracts may reflect a negative
regulation of El DNA binding activity.
The papillomavirus family comprises a large group of both
human and animal viruses. A characteristic feature of these
viruses is their ability to remain stably associated with the
host cell in an extrachromosomal fashion (7, 14). After an
initial period of amplification, replication of the viral genome
is tightly regulated with the cell cycle so that viral copy
number remains relatively constant (17, 35). This coordinate
replication of the viral and cellular genomes implies that the
virus is responsive to normal cellular control mechanisms.
Furthermore, the small size of papillomavirus genomes,
approximately 8,000 bp, suggests that these viruses will be
dependent on the cellular DNA replication machinery for
much of the actual enzymology of DNA synthesis. Work
with bovine papillomavirus (BPV) has established that the
viral genome can be manipulated in vitro and reintroduced
into mouse cells to assay both transient amplification (3, 17,
18, 36) and stable replication (2, 19, 20). All of these features
make papillomaviruses a valuable system for studying the
processes and regulation of eukaryotic DNA replication.
An essential step in understanding papillomavirus DNA
replication will be to identify and characterize viral gene
products critical for replication. Initial examination of the
BPV genome revealed that the El open reading frame (ORF)
shares homology with the simian virus 40 (SV40) large T
antigen, a known DNA binding protein involved in initiation
of viral DNA synthesis (6). Mutational analysis of the El
ORF confirmed that the El gene is essential for DNA
replication and suggests that the El ORF encodes at least
two products, a 5' product termed M and a 3' product termed
R (20). An El M protein which is consistent with the genetic
data has been identified (34), but a 3'-derived El R has not
yet been observed. More recently, a full-length El product
was detected as a nuclear protein and was shown to possess
ATP binding activity (31). Further work will be required to
determine whether or not there are additional El products
and to define the properties of the various El ORF proteins.
Elucidation of the functional roles of the El ORF products
will require biochemical characterization of the proteins
themselves. Several groups have expressed the El ORF in
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eukaryotic viral vectors in order to produce sufficient
amounts of protein for in vitro analysis (4, 22, 25). We have
now expressed the El ORF as a soluble RecA-El fusion
protein in Escherichia coli. By using an anti-El antiserum to
precipitate RecA-El-DNA complexes, we have demon-
strated specific binding of the RecA-El fusion protein to two
adjacent regions on the BPV genome. Strong binding to a
region which contains a minimal origin of DNA replication
(29) as well as known transcriptional regulatory sequences
(1, 16) occurred. Weak binding to the 5' adjacent region from
nucleotides 7457 to 7819 occurred. The detection of
RecA-El binding to functionally critical regions on the BPV
genome is consistent with a direct role for El in regulatory
activities via protein-DNA interactions.
MATERIALS AND METHODS
Plasmids, cells, and antisera. Plasmids pdBPV-l (26),
pDPV (10), pHPVla (11), and pHPV16 (8) were the sources
of BPV and of deer, human type la, and human type 16
papillomavirus (DPV, HPVla, and HPV16, respectively)
DNAs, respectively. Plasmid pGE374 contains the recA
promoter and the first 35 codons of the RecA sequence fused
out of frame to lacZ (15). pGE372 is a derivative of pGE374
in which the truncated recA gene is fused in frame with lacZ
to produce a RecA-p-galactosidase fusion protein (15).
pORFl is similar in design to pGE374 and contains the ompF
promoter and the first 33 codons of the OmpF sequence
fused out of frame to lacZ (37). ID13 and C127 cells were
obtained from P. Howley and were maintained in Dulbecco
modified Eagle medium-10% heat-inactivated fetal bovine
serum with 10 U of penicillin, 10 ,ug of streptomycin, and 2
,g of amphotericin B (Fungizone) per ml. Rabbit antisera
against RecA and 3-galactosidase were obtained from J.
Leibowitz and 5 Prime-*3 Prime, Inc., respectively.
Production of anti-El antisera. In order to generate pro-
teins for antiserum production, portions of the El ORF were
expressed by using the pORF1 vector system as described
by Weinstock et al. (37). Plasmid pEl249 was constructed by
ligating a fragment containing BPV sequences from nucleo-
tides 850 through 1073 into the SmaI site of the vector. This
plasmid expressed a tribrid fusion protein of the form
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FIG. 1. Structures of RecA-El fusion proteins. The El ORF is shown from the first methionine codon beginning at nucleotide 849 to the
end of the coding region at nucleotide 2663. This ORF encodes a 605-amino-acid protein. Below the El ORF are the predicted structures of
the RecA-El fusion proteins expressed by plasmids pGE1700T, 78A, and 83A. RecA-El has an amino terminus composed of 35 amino acids
encoded by the 5' end of the recA gene and S amino acids encoded by plasmid polylinker sequences (cross-hatched region). The El portion
ofRecA-El includes nucleotides 850 to 2605 of the El sequence and encodes 585 of the 605 amino acids in the complete El ORF. The resulting
RecA-El protein has a predicted molecular size of 75,000 Da. Mutants 78A and 83A have translation termination linkers inserted at
nucleotides 2245 and 2142, respectively, in the El sequence. The resultant truncated RecA-El fusion proteins should have molecular sizes
of 61,000 and 57,000 Da, respectively. Also shown is the location on the El protein to which the 5997 antiserum is directed (Anti-El249).
OmpF-El--galactosidase, where the El portion should
consist of amino acids 2 through 75 of the El protein. As a
control plasmid, a similar construct was created in which the
insert was a fragment from the El ORF inserted in the
incorrect orientation. This fragment had no termination
codons in this orientation, so it could express a tribrid fusion
protein, but the fusion protein would have no El ORF-
encoded amino acids. The control plasmid was designated
pNE.
Cultures of pE1249 and pNE were grown to an optical
density at 600 nm of 0.3 at room temperature, and then
plasmid protein expression was induced by shifting the
cultures to 42°C for 90 min (37). Whole-cell extracts were
prepared by suspending the cell pellets in sodium dodecyl
sulfate (SDS)-gel sample buffer (75 mM Tris-sulfate [pH 8.3],
15% glycerol, 2% SDS, 2% P-mercaptoethanol, 0.01% bro-
mophenol blue) at a ratio of 5 ml of buffer per g of wet cell
pellet and boiling the mixture for 5 min. Fusion proteins
were purified from the extracts by preparative gel electro-
phoresis (33) followed by elution with an Elutrap electroelu-
ter (Schleicher & Schuell). After dialysis against 5% (wt/vol)
ammonium bicarbonate and lyophilization, the fusion pro-
teins were dissolved in phosphate-buffered saline (PBS) to
200 pLg/ml. Rabbits were bled for preimmune sera and then
inoculated subcutaneously with 100 ,ug of purified fusion
protein emulsified in complete Freund's adjuvant. Boosts
were performed at 3-week intervals with 100 ,ug of protein
emulsified in incomplete Freund's adjuvant. Sera were col-
lected 7 to 10 days following each boost and stored at -20°C.
Serum from the rabbit inoculated with the protein expressed
by pE1249 was designated 5997, and serum from the rabbit
inoculated with the protein expressed by pNE was desig-
nated 5998.
Construction of RecA-El fusion proteins. The nearly full-
length El ORF was expressed by using the pGE374 vector
system (15). A 1,778-bp fragment derived from the El ORF
was obtained by digestion of pdBPV-1 with FnuDII followed
by partial digestion with SphI. The gel-purified fragment was
treated with Bal 31 to randomize the fragment length. The
resulting population of molecules was ligated into the SmaI
site of pGE374. Restriction analysis and DNA sequencing of
Lac' clones identified a recombinant that had the BPV El
ORF inserted in the proper orientation with both ends in
frame with vector sequences. This clone was designated
pGE1700.
To produce a RecA-El fusion protein without the 3-galac-
tosidase sequences, an NheI linker (New England BioLabs)
containing multiple translation termination codons was li-
gated to pGE1700 DNA (13), which had been linearized by
partial BamHI digestion. Lac- colonies were picked, and
plasmid DNA was screened by restriction digestion for the
presence of a termination linker at the El-lacZ junction. A
clone with the linker in the appropriate position was desig-
nated pGE1700T (Fig. 1). Sequencing of the E1-lacZ junc-
tion in pGE1700T confirmed the location of the linker.
Truncated forms of RecA-El were created by ligation of
the NheI linker into pGE1700 DNA linearized by random
DNase I digestion. Plasmid DNA from white colonies was
screened by restriction digestion for the presence of an NheI
linker inserted in the El ORF. The exact location of the
linker in each positive clone was determined by DNA
sequencing. Two mutants, 78A and 83A, had the NheI linker
inserted at BPV nucleotides 2245 and 2142, respectively, in
the El sequence of pGE1700.
Preparation of RecA-El extracts. E. coli MC1061 contain-
ing pGE374 or derivative plasmids was grown at 37°C to an
optical density at 600 nm of 0.4 in Luria-Bertani medium
with ampicillin at 50 ,ug/ml. Mitomycin was added to a final
concentration of 1.0 ,ug/ml, and the incubation continued for
2 h at 37°C to induce fusion protein production (15). Induced
cultures were chilled on ice for 10 min and then harvested by
centrifugation at 10,000 x g for 10 min at 4°C. Cell pellets
were washed once with ice-cold PBS and suspended in
ice-cold TNE (13 mM Tris HCI [pH 7.0], 0.1 mM EDTA, 10
mM NaCl) with 1 mM phenylmethylsulfonyl fluoride
(PMSF) at 1 ml of buffer per g of wet cell pellet. Cells were
lysed by two passages through a French pressure cell at
16,000 lb/in2. Lysates were collected on ice, and cell debris
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was removed by centrifugation at 27,000 x g for 10 min at
4°C. The soluble extract was made 50% with sterile glycerol
and stored at -20°C. DNA binding activity was stable for
several months at this temperature. For longer storage, small
aliquots were frozen at -70°C and used immediately upon
thawing. Total protein in the extracts was quantitated by the
Bradford assay (5) and was typically 3 to 5 ug/,Iu.
Immunoprecipitation of RecA fusion proteins. For immu-
noprecipitation, 40 RIu of extract prepared as described above
was incubated with 10 ,ul of the appropriate antiserum for 60
min on ice. Antibody-antigen complexes were collected by
the addition of 100 ,ul of 10% (vol/vol) protein A-Sepharose
(Pharmacia, Inc.). After incubation for 60 min at 4°C with
gentle agitation, the protein A-Sepharose was collected by
centrifugation for 1 min at 12,000 x g. The beads were
washed three times with 500 ,lI of cold 50 mM Tris HCI (pH
8.0)-S150 mM NaCl-1% Nonidet P-40-1 mM PMSF. The final
pellets were boiled for 5 min in 10 pul of SDS sample buffer
and spun for 1 min at 12,000 x g, and the supernatants were
electrophoresed on 15% SDS-polyacrylamide gels. The
RecA fusion proteins were visualized by Western blotting
(immunoblotting) with appropriate antisera.
Western blots of RecA fusion proteins. Immunoprecipitates
or direct samples of extracts were electrophoresed on 15%
SDS-polyacrylamide gels, and the proteins were transferred
from the SDS gels to Optibind membranes (Schleicher &
Schuell) by electrophoresis at 2.5 mA/cm2 of gel in a
Polyblot unit (American Bionetics, Inc.). Immunological
detection of proteins on the filters was performed with an
Auroprobe BLplus kit followed by IntenSE BL silver en-
hancement (Janssen) as described by the manufacturer.
Primary antisera were as indicated in the figure legends and
were used at a 1:1,000 dilution.
Preparation of ID13 and C127 extracts. ID13 or C127 cells
were grown to near confluency in 150-cm2 flasks. Prior to
harvesting of cells, each flask was washed once with 10 ml of
ice-cold PBS and once with 10 ml of ice-cold hypotonic
buffer (20 mM Tris HCl [pH 7.6], 5 mM KCl, 1.5 mM MgCl2,
0.1 mM dithiothreitol). Cells were scraped into cold hypo-
tonic buffer (10 ml per flask) and pelleted by centrifugation at
1,200 x g for 10 min at 4°C. Cell pellets from each flask were
suspended in 500 plI of hypotonic buffer and then lysed by
the addition of 500 pI of hypotonic buffer supplemented with
1% Triton X-100 and 2 mM PMSF. Samples were incubated
in the lysis buffer for 1 min on ice, and then nuclei were
pelleted by centrifugation for 5 min at 4°C in a microfuge.
Nuclei were extracted by resuspension in 50 ,ul of hypotonic
buffer supplemented with 350 mM NaCl and 1 mM PMSF.
Resuspended nuclei were incubated for 20 min on ice and
then pelleted for 10 min at 4°C in a microfuge. The superna-
tants were made 50% with sterile glycerol and stored in small
aliquots at -70°C. The total protein concentration in the
nuclear extracts was generally 3 to 6 pug/,ul.
Digestion and labeling of DNA. All plasmid DNAs were
isolated by standard procedures (24) and were CsCl gradient
purified. SV40 DNA was prepared from virus-infected cells
as previously described (32). For end labeling, 1 pug of DNA
was digested with StyI or AvaIl to generate 5' overhangs.
The overhangs were filled by extension of the 3' strands with
6 U of Sequenase (USB Corp.) in a 30-pA reaction mixture
containing 1 pug of restriction enzyme-digested DNA; 19 mM
Tris HCl (pH 7.8); 38 mM NaCl; 7.6 mM MgCl2; 5 mM
dithiothreitol; 0.72 puM (each) dATP, dCTP, and dTTP; and
0.32 ,uM [32P]dGTP (3,000 Ci/mmol; ICN, Inc.). Extension
reaction mixtures were incubated for 10 min at room tem-
perature, stopped by the addition of 10 RI of 200 mM EDTA,
and diluted to 1.0 ml with TNE buffer. Unincorporated label
was removed by centrifugation of the DNA twice in a
Centricon-30 (Amicon) as specified by the manufacturer.
Labeled DNA was adjusted to 10 ng/,u with TNE and stored
at -20°C. For subdigestion of StyI-cut pdBPV-1, labeled
DNA was incubated with various restriction enzymes under
the appropriate reaction conditions. After digestion, the
DNA was phenol extracted, alcohol precipitated, and redis-
solved in TNE to the original concentration of 10 ng/ul.
DNA binding assay. To assay DNA binding, 15 to 30 ,ug of
total protein (from bacterial or ID13 extracts) was incubated
with 50 ng of labeled DNA in 25 plA of TNE containing 150
mM NaCl and 1,500 ng of unlabeled sheared salmon sperm
DNA (5 Prime-*3 Prime, Inc.). Binding reaction mixtures
were incubated for 30 min at 25°C and then returned to an ice
bath. Appropriate serum (10 pA) was added, incubation was
continued for 60 min on ice, and then 100 pA of a protein
A-Sepharose (Pharmacia) suspension (10% vol/vol in PBS)
was added. After addition of the protein A-Sepharose,
samples were incubated for 60 min at 4°C with gentle
agitation. The Sepharose beads were collected by centrifu-
gation for 1 min at 4°C; washed three times with 1 ml of TNE
containing 200 mM NaCl, 0.25% Nonidet P-40, and 5 ,ug of
sheared salmon sperm DNA per ml; and washed once with 1
ml of TNE. Washed beads were extracted for 15 min at 37°C
with 10 pA of TBE sample buffer (89 mM Tris base, 89 mM
boric acid, 2.5 mM EDTA, 10% glycerol, 2.7% xylene
cyanol, 2.4% bromophenol blue, 1% SDS) and pelleted by
centrifugation for 1 min at room temperature in a microfuge,
and the supernatants were electrophoresed on either 1%
agarose gels or 8% nondenaturing polyacrylamide gels by
using standard Tris-borate buffers (24). After electrophore-
sis, agarose gels were fixed for 30 min in 7.0% trichloroacetic
acid, rinsed twice for 5 min with distilled water, and dried.
Acrylamide gels were dried directly without fixing. Dried
gels were exposed for autoradiography with intensifying
screens.
RESULTS
Expression of the RecA-El fusion protein. To produce a
BPV El-related protein for biochemical analysis, the El
gene was first cloned into the bacterial expression vector
pGE374. Restriction analysis and partial sequencing of the
resulting plasmid, pGE1700, confirmed that the cloned El
gene fragment was present in the correct reading frame with
respect to the vector recA and lacZ sequences (not shown).
pGE1700 expressed a 188,000-molecular-weight protein
(188K protein) that was immunoreactive with both anti-
RecA and anti-,-galactosidase sera (Fig. 2); no such protein
was expressed in cells containing the parental plasmid,
pGE374. As expected for this vector system, expression of
the 188K protein was induced by mitomycin (not shown).
The size and immunoreactivity pattern of the 188K protein,
along with its induction properties, confirmed that it was a
RecA-El-p-galactosidase fusion protein expressed from the
constructed plasmid.
To eliminate the P-galactosidase portion of the RecA-El-
,-galactosidase fusion protein, a translation termination
linker was inserted at the E1-lacZ junction of pGE1700 to
generate pGE1700T. Sequencing of the plasmid-insert junc-
tions indicated that pGE1700T should encode a 75K
RecA-El fusion protein consisting of an amino terminus
derived from both recA (35 amino acids) and vector se-
quences (5 amino acids) followed by amino acids 2 to 585 of
the El ORF (Fig. 1). pGE1700T no longer expressed the
J. VIROL.
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FIG. 2. Immunological identification of RecA fusion proteins.
Whole-cell extracts were prepared from mitomycin-induced cells
harboring plasmids pGE374, pGE1700, and pGE1700T. Samples of
each extract were electrophoresed on 15% SDS gels and analyzed
by Western blotting with either anti-p-galactosidase or anti-RecA as
indicated. The positions of molecular size markers are shown on the
left (in kilodaltons), and the RecA fusion proteins are indicated on
the right.
188K protein observed with pGE1700 but did express a new
73K protein reactive with anti-RecA and not reactive with
anti-B-galactosidase (Fig. 2). Again, the size and immuno-
reactivity pattern confirmed that the 73K protein was the
predicted RecA-El fusion protein. The RecA-El fusion
protein could be extracted in a soluble form from mitomycin-
induced cultures and was therefore suitable for biochemical
characterizations of El activities in vitro.
Production of an anti-El antiserum. To facilitate the bio-
chemical analysis of El proteins in vitro, rabbit anti-El
antisera were raised against five different subregions of El
(38). Production of one of the antisera, 5997, is described in
Materials and Methods; production and characterization of
the remaining antisera will be reported elsewhere. All of the
DNA binding studies presented in Fig. 4 through 8 utilized
El antiserum 5997, though identical results have been ob-
tained with the other sera (not shown).
Antiserum 5997 was raised against an OmpF-E1-p3-galac-
tosidase fusion protein containing El amino acids 2 through
75. Control antiserum 5998 was obtained from a rabbit
inoculated with a similar fusion protein except that the insert
did not encode El amino acid sequences. To evaluate these
antisera, 5997 and 5998 were tested for immunoreactivity
with RecA-El. Since the only sequences in common be-
tween RecA-El and the immunogen were the El sequences,
recognition of RecA-El by 5997 would indicate the presence
of anti-El antibodies in this serum. As shown in Fig. 3, 5997
postimmune serum immunoprecipitated RecA-El, while
both of the preimmune sera and the 5998 postimmune serum
failed to precipitate this fusion protein. Further analysis of
these sera by direct Western blotting again demonstrated
that only the 5997 postimmune serum detected the RecA-El
protein (not shown). Failure of antiserum 5998 to detect the
RecA-El protein indicated that antibodies against the OmpF
and P-galactosidase portions of the immunogen were not
cross-reacting with El sequences. Consequently, the 5997
antiserum must contain antibodies directed specifically
against El sequences.
RecA-El protein specifically binds BPV DNA. Genetic
FIG. 3. Detection of RecA-El with an anti-El antiserum. Whole-
cell extracts were prepared from mitomycin-induced cultures of
MC1061 harboring pGE374 (-) or pGE1700T (+). Extracts were
immunoprecipitated with preimmune (PI) or postimmune (I) sera as
indicated. The immunoprecipitates were electrophoresed on 15%
SDS-polyacrylamide gels, and the RecA-El fusion protein was
visualized by Western blotting with anti-RecA serum. The position
of RecA-El is indicated by the arrowhead.
analysis has confirmed that the El ORF product(s) is re-
quired for BPV DNA replication (19, 20, 36). In addition,
there is sequence homology between the El protein and the
SV40 large T antigen (6), suggesting that El may possess
biochemical and functional activities similar to those of T
antigen. Since T antigen mediates its replicative function via
direct binding to the SV40 origin region (22, 28, 30), we
attempted to determine if El also possessed a site-specific
DNA binding activity. To investigate the DNA binding
capability of RecA-El, whole-cell extracts were prepared
from cells expressing RecA-El (pGE1700T), a RecA-P-
galactosidase fusion protein (pGE372), or no fusion protein
(pGE374). Extracts were incubated with a radiolabeled Styl
digest of cloned BPV DNA and then were immunoprecipi-
tated with the various sera (Fig. 4). For the extract prepared
from cells expressing the parental plasmid, no specific pre-
cipitation of DNA fragments was detected when anti-RecA
or the 5997 preimmune or immune sera were used (lanes 4 to
6). Some precipitation of the Styl D fragment was observed,
but the amount of fragment D precipitated was inconsistent
and was detected even in the absence of serum, indicating
that it was nonspecific background. In contrast, when the
same precipitations were performed with extracts containing
RecA-El, both anti-RecA and 5997 immune serum but not
5997 preimmune serum precipitated the Styl B fragment
(lanes 7 to 9). The diminished precipitation of fragment B by
anti-RecA (lane 8) compared with that by 5997 immune
serum (lane 9) correlated with the less-effective precipitation
of RecA-El by anti-RecA relative to that elicited by 5997
serum (38). The observation that fragment B was precip-
itated only when RecA-El was both present and immuno-
precipitated strongly implicated the RecA-El protein in
binding to this region of the BPV genome.
Further evidence that RecA-El was binding to the Styl B
fragment came from binding studies with two truncated
forms of RecA-El. Mutants 78A and 83A had translation
termination linkers inserted at nucleotides 2245 and 2142,
respectively, in the El sequences of plasmid pGE1700 (Fig.
1). These mutants should produce RecA-El proteins lacking
the carboxyl-terminal 139 and 173 amino acids, respectively,
of the El ORF. Western blot analysis of extracts from cells
ant RecA
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FIG. 4. Binding to the Styl B fragment of pdBPV-1 is dependent
on the presence of RecA-El. Binding to StyI-digested pdBPV-1 was
performed with extracts from pGE372 (lanes 1 to 3), pGE374 (lanes
4 to 6), and pGE1700T (lanes 7 to 9). pGE372, pGE374, and
pGE1700T expressed a RecA-3-galactosidase fusion protein, no
RecA fusion protein, and the RecA-El fusion protein, respectively.
The immunoprecipitation step was performed with preimmune
serum (lanes 1, 4, and 7), anti-RecA serum (lanes 2, 5, and 8),
anti-p-galactosidase serum (5 Prime-*3 Prime, Inc.) (lane 3), or 5997
serum (lanes 6 and 9). Precipitated fragments were electrophoresed
on a 1% agarose gel and detected by autoradiography. Lane M
consists of a portion of the input Styl digest of pdBPV-1, with the
digestion fragments labeled A to G. The specifically bound Styl B
fragment is indicated with an arrowhead.
containing 78A and 83A confirmed that each plasmid ex-
pressed a fusion protein of the correct predicted molecular
weight (Fig. SA). DNA binding studies revealed that extracts
containing either of the truncated RecA-El proteins had no
significant DNA binding activity compared with extracts
containing full-length RecA-El (Fig. SB). When the same
conditions as for the DNA binding assay were used, 5997
immune serum effectively immunoprecipitated each trun-
cated fusion protein, demonstrating that the failure to detect
DNA binding was not due to inadequate immunoprecipita-
tion (not shown). The elimination of DNA binding activity
by mutations which caused truncation of the RecA-El
protein confirmed that the binding to the StyI B fragment
was in fact due to the RecA-El protein. In addition, the lack
of DNA binding activity by the truncated fusion proteins
indicated that carboxyl-terminal sequences in El were re-
quired for the observed DNA binding activity.
While the results described above indicated that the El
portion of the RecA-El fusion protein was critical for DNA
binding activity, these data did not address the contribution
of the RecA portion of the fusion protein. To ensure that the
observed DNA binding activity was not intrinsic to the short
RecA sequence of the fusion protein, a RecA-,3-galactosi-
dase fusion protein was assayed for binding to BPV DNA.
The RecA-3-galactosidase fusion protein had the same
RecA portion as RecA-El, yet no binding to BPV DNA was
detected when RecA-,-galactosidase was precipitated with
either anti-RecA or anti-p-galactosidase (Fig. 4, lanes 2 and
3). As for the truncated fusion proteins, failure to detect
DNA binding by the RecA-,B-galactosidase protein was not
FIG. 5. Examination of truncated RecA-El fusion proteins. (A)
Extracts from cells harboring plasmids pGE374, pGE1700T, and the
termination constructs 78A and 83A were examined by Western
blotting as described in Materials and Methods. The source of the
extract is indicated above each lane. Molecular size markers in
kilodaltons are indicated at the left, and positions of the fusion
proteins are indicated on the right. Mutants 78A and 83A expressed
truncated RecA-El proteins of the predicted molecular sizes. (B)
Extracts from pGE374, pGE1700T, 78A, and 83A were tested for
DNA binding as described in Materials and Methods. For this
experiment, the pdBPV-1 DNA was digested with Avall prior to end
labeling. For each extract, precipitation of protein-DNA complexes
was performed with 5997 serum. Precipitated DNA fragments were
analyzed on an 8% polyacrylamide gel, a portion of which is shown.
The source of the protein extract used for the binding reaction is
indicated above each lane. Lane M is a sample of the input
AvaIl-digested pdBPV-1 DNA. Only the extract containing full-
length RecA-El (lane 1700T) exhibited DNA binding. Strong bind-
ing to a 219-bp fragment and weak binding to a 362-bp fragment
occurred as indicated.
due to lack of precipitation, since both anti-RecA and
anti-,B-galactosidase precipitated this fusion protein (not
shown). The absence of binding activity by the RecA-p-
galactosidase fusion protein confirmed that the mere pres-
ence of RecA sequences on a fusion protein was insufficient
to confer binding to BPV DNA. In addition, it should be
noted that all of the extracts utilized in these studies con-
tained endogenous RecA protein, yet anti-RecA precipitated
the StyI B fragment only from extracts containing the
full-length RecA-El fusion protein. Clearly, this established
that neither endogenous RecA nor the RecA portion of the
fusion proteins had any specific affinity for the BPV Styl B
fragment.
The specificity of RecA-El binding to the Styl B fragment
was examined by a competition experiment wherein increas-
ing amounts of unlabeled, nonspecific DNA were added to
the binding reactions (Fig. 6). In the absence of competitor,
RecA-El showed a general DNA binding capacity. How-
ever, with increasing amounts of competitor DNA, binding
was greatly reduced for all fragments except B. Binding to
fragment B was reduced only 50% in the presence of
30-fold-excess unlabeled DNA, while precipitation of other
fragments was reduced by 85 to 90%. Furthermore, at least
a portion of the apparent residual binding to other fragments,
especially fragment D, represented nonspecific precipita-
tion, since it occurred in the absence of RecA-El as well as
with preimmune serum (see Fig. 4, for example). These
competition results indicated that the observed precipitation
of the StyI B fragment reflected a specific interaction be-
tween RecA-El and sequences within this fragment.
Localization of RecA-El binding on the BPV genome. The
studies described above demonstrated specific binding of
RecA-El to the Styl B fragment of the BPV genome.
However, this StyI fragment spanned nucleotides 7657 to
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FIG. 6. Effect of competitor DNA on binding of RecA-El to BPV sequences. (A) RecA-El binding to pdBPV-1 DNA was assayed by
immunoprecipitation of protein-DNA complexes with 5997 serum as described in Materials and Methods. The binding reactions contained 50
ng of a radiolabeled StyI digest of pdBPV-1 DNA and increasing amounts of unlabeled competitor DNA as indicated above the lanes. The
competitor DNA shown here was sheared salmon sperm DNA, but identical results have been obtained with poly(dI dC) (Pharmacia).
Precipitated DNA fragments were electrophoresed on a 1% agarose gel and detected by autoradiography. Lane M contains a portion of the
input StyI-digested pdBPV-1 DNA. Styl fragments A to G are indicated. (B) Fragments A, B, and D were excised from each lane in panel
A and quantitated by Cerenkov counting of the radioactivity present in each gel slice. The quantity of each fragment bound in the presence
of increasing competitor was plotted as a percentage of the amount bound in the absence of competitor (panel A, lane 0).
2767 on the BPV map, a large region containing numerous
cis elements. To localize binding within this large region, the
StyI fragment was subdivided with EcoRI, NruI, or HpaI
prior to the immunoprecipitation binding assay (summarized
in Fig. 7A). Each of these enzymes cut once within the StyI
B fragment to generate two labeled subfragments. For both
the EcoRI and NruI digestions, binding was to the fragment
derived from the 5' end of the StyI B fragment. For the HpaI
digestion, however, neither of the two fragments generated
by subdigestion were bound well by RecA-El. To confirm
this localization, binding of RecA-El to Avall-digested BPV
DNA was tested (Fig. 7B). Binding was primarily to a 219-bp
AvaIl fragment derived from nucleotides 7819 to 93 on the
BPV map. The observed strong binding to the 219-bp frag-
ment, which contained the HpaI site, was consistent with
the results from subdigestion of the StyI B fragment. As with
the StyI B fragment, digestion of the 219-bp AvaIl fragment
with HpaI resulted in no binding to either subfragment,
suggesting that the binding site(s) may reside at or near the
HpaI recognition site.
In addition to the 219-bp fragment, a small amount of the
362-bp Avall fragment was consistently precipitated with
anti-El sera (see Fig. 5 and 8, for example). Precipitation of
the 362-bp fragment was not observed with preimmune sera
or in the absence of RecA-El (not shown). Weak precipita-
tion of other fragments was observed inconsistently, oc-
curred with preimmune sera as well as anti-El sera, and
occurred in the absence of RecA-El (not shown). These
results indicated that there was specific, albeit weak, binding
by RecA-El to the 362-bp fragment, while other fragments
occasionally observed were apparently the result of nonspe-
cific precipitation. The 362-bp AvaIl fragment consisted of
nucleotides 7466 to 7818 on the BPV genome map, which
was the region adjacent to the sequences present in the
219-bp fragment. From the results of binding to either StyI-
or AvaII-digested BPV DNA, it was apparent that the
RecA-El fusion protein bound specifically to a very limited
portion of the BPV genome toward the early end of the
upstream regulatory region.
RecA-El binding to other papillomavirus genomes. To
investigate whether the RecA-El fusion protein derived
from BPV El could bind to other papillomavirus genomes,
the immunoprecipitation binding assay was performed with
AvaIl-digested DPV, HPVla, and HPV16 DNAs (not
shown). As controls, binding to pBR322 and SV40 DNA was
tested also (not shown). Binding comparable to that ob-
served for the BPV 219-bp Avall fragment was not detected
with any of the heterologous DNAs, even the closely related
DPV, suggesting a high degree of specificity between BPV
El and its cognate DNA. There were, however, some
weakly precipitated fragments reproducibly observed with
the other papillomavirus DNAs. These fragments were not
detected when the immunoprecipitations were performed
with control serum or in the absence of RecA-El, indicating
that they represented specific binding by RecA-El. The
weak binding to these heterologous fragments was similar in
degree to the binding observed for the 362-bp BPV fragment,
but the significance of this observation has not yet been
determined.
DNA binding by El from ID13 cells. The DNA binding
studies described above were conducted with a bacterially
expressed El-related protein. To compare DNA binding by
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FIG. 7. Localization of RecA-El binding on the BPV genome. (A) Summary of the results of binding of RecA-E1 to different restriction
fragments from the BPV genome as assayed by immunoprecipitation with 5997 serum. The restriction enzymes used to generate the fragments
are listed on the left. The relative genomic positions of the fragments are indicated, with the ends of the fragments identified by their BPV
nucleotide numbers. Fragment lengths are given in base pairs. The ability of RecA-El to bind to each fragment is indicated on the right, with
a plus indicating that binding occurred and a minus indicating that no binding could be detected. For the StyI-HpaI digestion, neither
subfragment was bound strongly, but weak binding, usually to the 2,763-bp subfragment, was occasionally observed. The question marks
denote uncertainty about the binding results with these two StyI fragments. (B) pGE1700T extracts were incubated with AvaIl (lane 1)- or
AvaII-HpaI (lane 3)-digested pdBPV-1 DNA and precipitated with 5997 serum as described in Materials and Methods. Lanes 2 and 4 contain
portions of the input AvaIl- and AvaII-HpaI-digested DNAs, respectively. The two subfragments produced by HpaI digestion of the 219-bp
AvaIl fragment are marked with arrowheads.
RecA-El with DNA binding by authentic El protein(s),
nuclear extracts from ID13 cells were prepared as a source
of El protein(s) expressed in eukaryotic cells. ID13 cells are
a BPV-transformed derivative of C127 mouse cells that
express full-length BPV El protein (31). Nuclear extracts
from ID13 cells and the parental C127 cells were tested for in
vitro DNA binding under the same conditions as were used
for RecA-El (Fig. 8). Immunoprecipitation of the ID13 and
C127 extracts with 5997 anti-El serum demonstrated no
significant binding to the 219-bp fragment, but the ID13
extract did exhibit binding to the 362-bp fragment. No
binding to the 362-bp fragment was detected with preimmune
serum or with the control C127 extract, indicating that the
binding observed with the ID13 extract was El dependent.
Binding of the ID13 extract to the 362-bp fragment in the
absence of binding to the 219-bp fragment is in contrast to
binding of RecA-El, which binds strongly to the 219-bp
fragment and only weakly to the 362-bp fragment.
DISCUSSION
The functional role of the BPV El ORF in DNA replica-
tion (19, 20, 36) and transcriptional control (12, 27) suggests
the possibility that El proteins have sequence-specific DNA
binding ability. To examine this question directly, we ex-
pressed the BPV El ORF in the form of a RecA-El fusion
protein in E. coli. Using an in vitro immunoprecipitation
assay, RecA-El was shown to bind specifically to a limited
region of the BPV genome. Binding was primarily to a
219-bp AvaII restriction fragment spanning nucleotides 7819
to 93 on the BPV genome map. Digestion of this fragment
with HpaI, which cuts between nucleotides 3 and 4, de-
stroyed the ability of RecA-El to bind to this region,
suggesting that the binding site was at or near the HpaI
recognition sequence. No strong binding to heterologous
papillomavirus DNAs was detected, even though there was
significant sequence conservation in the HpaI region. Con-
sequently, the interaction of the BPV El protein with its
cognate DNA must be extremely specific.
The biological significance of the interaction of RecA-El
and the BPV HpaI region has not been established, but the
location of binding correlated well with the functional origin
C127 ID13 1700T
Pl Pi Pl M
QNWAO ~~~362
219
FIG. 8. Comparison ofDNA binding by authentic El protein and
RecA-El. DNA binding was performed under standard conditions
using pGE1700T extracts (lanes 1700T) or nuclear extracts from
ID13 cells or C127 cells. The input DNA was AvaIl-digested
pdBPV-1, as shown in lane M. Precipitation of protein-DNA com-
plexes was with preimmune serum (PI) or 5997 serum (I). The
positions of the 219- and 362-bp fragments are indicated.
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of BPV replication recently defined by Stenlund and Ustav
(29). Using a transient replication assay, they mapped a BPV
El-dependent functional origin to a 100-bp region which
includes the HpaI site. Linker insertions at the HpaI site
inhibited replication, indicating that critical cis elements are
located in this region. The failure of RecA-El to bind to
HpaI-cut DNA suggests that the replication-minus pheno-
type of Stenlund's HpaI mutants may be due to an inability
to bind El protein. Consistent with this is their observation
that the analogous HpaI-containing fragment from DPV
cannot substitute for the BPV fragment in the BPV replica-
tion assay (29) and our observation that RecA-El did not
bind well to this region from DPV (not shown).
The juxtaposition of an El binding region with the repli-
cation origin is consistent with a direct role for El in the
DNA replication process such as has been determined for
the SV40 T antigen (22, 28, 30). Precise mapping of the
binding site(s) for RecA-El along with mutational analysis of
the binding region should help clarify the relationship be-
tween binding and replication activity. Furthermore, the
structural homologies between El and T antigen suggest that
some of the functions of El in DNA replication will be
similar to those defined for the well-studied T antigen.
Biochemical characterization of the RecA-El protein should
be useful for determining such activities.
In addition to RecA-El binding to the 219-bp fragment,
weak binding to a 362-bp AvaII fragment containing the
adjacent region from nucleotides 7458 to 7818 was detected.
Recently, Mohr et al. observed weak binding of a baculovi-
rus-expressed El protein to a similar fragment containing
nucleotides 7477 to 7796 (21). This weak binding to the
7477-to-7796 fragment was enhanced by the addition of E2
protein, apparently through the formation of El-E2 com-
plexes (21). These results with both RecA-El and the
baculovirus-expressed El protein suggest that in the absence
of E2 protein, El has an intrinsic but weak interaction with
BPV sequences in the region from approximately nucleo-
tides 7450 to 7800. Furthermore, our observation that the
362-bp fragment was bound by ID13 extracts precipitated
with anti-El serum is consistent with an interaction between
an authentic El protein and this region of the BPV genome.
However, as our ID13 extracts likely contain E2 as well as
El protein, the binding we observed may reflect El plus E2
activity. Further experiments to address the effect of El-E2
interactions on El DNA binding activity are in progress.
The significance of binding by RecA-El and the baculovi-
rus-expressed El protein to the region from nucleotides 7457
to 7818 is unclear. While two-dimensional analysis of repli-
cating DNA structures indicates that initiation of BPV
replication occurs in this region (39), these sequences are not
required in the functional replication assay (29). Conse-
quently, the role of sequences in this region for DNA
replication and the functional significance of El binding to
these sequences remain to be determined.
While this paper was in preparation, two additional groups
reported on the DNA binding properties of El proteins
expressed from vaccinia virus (25) or baculovirus vectors
(4). Neither group was able to demonstrate specific DNA
binding by the expressed El proteins. The limited (21) or
inapparent (4, 25) site-specific DNA binding ability of El
protein expressed in eukaryotic systems is in sharp contrast
to the binding exhibited by the bacterially expressed
RecA-El protein. RecA-El bound specifically to the 219-bp
AvaIl fragment of BPV which contains the functional origin
of replication, while none of the previously reported eukary-
otically expressed El proteins have demonstrated this activ-
ity. However, if El binding to the origin is a requirement for
replication, why then do the El proteins expressed in
eukaryotic systems (from ID13 cells or from baculovirus or
vaccinia virus vectors) fail to exhibit significant origin DNA
binding activity? While differences in experimental condi-
tions for DNA binding or in the functional stability of the
examined El proteins could explain this discrepancy, more
biologically interesting possibilities exist. Given the coordi-
nated replication of BPV and cellular DNA during the cell
cycle (9), there must be mechanisms which normally limit
BPV replication. One mechanism may be to regulate El such
that El is able to bind to the origin region only for a transient
period during the cell cycle. This might be accomplished by
reversible posttranslational modification (e.g., phosphoryla-
tion-dephosphorylation) of El such has been observed for
SV40 T antigen (23), by use of cellular proteins which
interact with El and/or the El binding site(s) to regulate El
binding, or by ligand-induced changes in El binding activity.
Consequently, El expressed from eukaryotic vectors may
already be subjected to the negative regulatory mecha-
nism(s) and therefore have limited origin DNA binding
activity. In contrast, the bacterially expressed RecA-El
would have escaped the normal control(s) imposed in eu-
karyotic cells and could exhibit the DNA binding activity
intrinsic to this protein. Experiments to address these pos-
sibilities are in progress.
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